Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. - Wikidata - awgldk - TriplyDB

Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

http://www.wikidata.org/entity/Q43640226

about

Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.Histologic Grade and Decrease in Tumor Dimensions Affect Axillary Lymph Node Status after Neoadjuvant Chemotherapy in Breast Cancer Patients Imaging of the axilla before preoperative chemotherapy: implications for postmastectomy radiation.Role of imaging in neoadjuvant therapy for breast cancer.Preoperative axillary lymph node evaluation in breast cancer patients by breast magnetic resonance imaging (MRI): Can breast MRI exclude advanced nodal disease?Axillary Ultrasound in the Management of the Newly Diagnosed Breast Cancer Patient.Immediate Reconstruction in Inflammatory Breast Cancer: Challenging Current Care.Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients Before Neoadjuvant Chemotherapy: A Preliminary Study.Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

P2860

Q26769835-F4617AD9-1ADE-438F-A7FB-42397C3037C8 Q28072923-F1E0AC28-1006-4199-B812-D588CFC9E51F Q33730822-85646A31-0EDC-45C2-916D-949A0DA51D29 Q36295737-1BA1287D-C7CC-43BE-9BF0-CBF405954CF4 Q36441562-E10A78DA-91C6-414A-AF42-67BC163BD468 Q38257478-991ABF22-713B-4159-9974-DAE8AD3C1143 Q38366386-D6C2195D-2DC8-4731-AD0A-D4813FCA2080 Q38417564-DC133770-98B8-4105-BF80-985582CC12BD Q38591911-3BEB173E-B5B7-4EA8-9802-AF5D193657CC Q38957313-C60FBA27-9F20-4D78-9FC0-FAE52F7A4600 Q39019484-C18C968F-CEAD-4099-A6FD-E046907F9011 Q41436889-773B913D-8EA0-4CC0-BE1D-5C51A144A24C Q49580314-5CAD3D0C-0843-4968-AFF4-EE4F70060B07 Q49912739-D0CC896E-0705-4468-8CD2-23F94EAA39A5 Q50052437-DFB180A2-A53A-413D-893D-3EEA74CBAAC7 Q53099965-B0B4DAB4-603E-4C94-AEED-9C857D78F493 Q55003756-DE130903-5B68-48AD-8923-2C025C17C889

P2860

Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

http://www.wikidata.org/entity/Q43640226

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Imaging response and residual ...... apy for primary breast cancer.

@en

Imaging response and residual ...... apy for primary breast cancer.

@nl

type

label

Imaging response and residual ...... apy for primary breast cancer.

@en

Imaging response and residual ...... apy for primary breast cancer.

@nl

prefLabel

Imaging response and residual ...... apy for primary breast cancer.

@en

Imaging response and residual ...... apy for primary breast cancer.

@nl

P1433

Q43640226-3538D27D-9BC2-4073-8947-33292800F8EB

P1476

Q43640226-3ECB33C5-505E-44C6-ACE6-4E5FEC6BD7DC

P2093

Q43640226-141EDBDF-2A2C-4F91-8B16-87ADA1CE94C1

Q43640226-42A14216-EFB7-419D-8535-8D5D5B854A49

Q43640226-4ADDB027-725B-4A3A-BC38-EDEE9FAA4207

Q43640226-CC32B6F7-F38B-4F52-95EF-C3FD9B7152A4

Q43640226-F041D737-5294-4EE0-8576-FFC1B2789B8B

P2860

Q43640226-0149990F-208E-417B-A28E-FD2475F7928A

Q43640226-1FC2407A-C638-45B4-A3CB-C15CC16F4831

Q43640226-36B1AE4B-9CE6-4CBA-8F7C-746A7360B762

Q43640226-63C89305-720D-41EE-9DE1-B02D56E51C7E

Q43640226-68705BE3-F184-4ACD-A2D7-B57B19549F79

Q43640226-6B8F3DD1-1587-443B-BD6E-8280EC06FFEF

Q43640226-79525602-A542-4A3C-8D4F-3772FFB05559

Q43640226-D67C1493-EAB4-4A7E-A867-61549D29B6D0

Q43640226-F1286FC9-2F23-48EB-810D-27BC75ACB00C

P2888

Q43640226-2A949865-9AC3-4DAA-8D86-0BB94089168E

P304

Q43640226-0C219555-9CC4-4CE4-8698-AA58E5A024A6

P31

Q43640226-962C5DB2-F533-4B33-B8A5-046961939F0A

P356

Q43640226-7DD5942C-7187-4219-9079-77BF964F3407

P433

Q43640226-F543C0BC-EAD2-479A-86E3-A92DBD58B3B8

P478

Q43640226-AD35417B-8061-4166-8483-7439A0931B64

P577

Q43640226-1008AA40-C0D7-4FD6-9C57-1022B62BA90C

P6179

Q43640226-BB63791F-726A-4D9C-A504-48C890C5EC72

P698

Q43640226-AF9B18E4-E3CF-4DB7-80AB-ECA044C312C2

P921

Q43640226-B1871360-6594-4407-AB9E-5D68C64727E8

P356

S10434-013-3118-Z

P1433

Annals of Surgical Oncology

P1476

Imaging response and residual ...... apy for primary breast cancer.

@en

P2093

Judy C Boughey

http://www.w3.org/2001/XMLSchema#string

Katie N Jones

http://www.w3.org/2001/XMLSchema#string

Katrina N Glazebrook

http://www.w3.org/2001/XMLSchema#string

Sejal S Shah

http://www.w3.org/2001/XMLSchema#string

Tina J Hieken

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review.

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

Enhanced sonographic imaging to diagnose lymph node metastasis: importance of blood vessel volume and density.

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast?

P2888

s10434-013-3118-z

P304

3199-3204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-013-3118-Z

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046966349

http://www.w3.org/2001/XMLSchema#string

P698

23846781

http://www.w3.org/2001/XMLSchema#string

P921